drugset / Trial / NCT03238534
Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS
Phase 4
Completed
275 enrolled
Aboca
BMR Genomics · collabDoppel Farmaceutici · collabUniversity of Roma La Sapienza · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Comparison of Neobianacid® clinical efficacy to omeprazole in relief of heartburn or epigastric pain
Timeline
- Start
- 2017-09-12
- Primary completion
- 2021-09-03
- Completion
- 2021-09-03
Publications
- Corazziari ES, Gasbarrini A, D'Alba L, D'Ovidio V, Riggio O, Passaretti S, Annibale B, Cicala M, Repici A, Bassotti G, Ciacci C, Di Sabatino A, Neri M, Bragazzi MC, Ribichini E, Iovino P, Badiali D. Poliprotect in the PPI Deprescription Phase of Endoscopy-Negative Heartburn and Epigastric Pain Syndrome Patients: An RCT Post Hoc Analysis. Neurogastroenterol Motil. 2026 Jun;38(6):e70370. doi: 10.1111/nmo.70370.
- Corazziari ES, Gasbarrini A, D'Alba L, D'Ovidio V, Riggio O, Passaretti S, Annibale B, Cicala M, Repici A, Bassotti G, Ciacci C, Di Sabatino A, Neri M, Bragazzi MC, Ribichini E, Radocchia G, Iovino P, Marazzato M, Schippa S, Badiali D. Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. Am J Gastroenterol. 2023 Nov 1;118(11):2014-2024. doi: 10.14309/ajg.0000000000002360. Epub 2023 Jun 13.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Omeprazole | Other / unclassified | 20 mg | Oral |